These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 33507515)

  • 81. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
    Jain P; Wang ML
    Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma.
    Shishodia S; Amin HM; Lai R; Aggarwal BB
    Biochem Pharmacol; 2005 Sep; 70(5):700-13. PubMed ID: 16023083
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Unmet needs in the treatment of mantle cell lymphoma.
    Rosen ST; Link BK; Fowler NH
    Clin Adv Hematol Oncol; 2013 Nov; 11(11 Suppl 18):1-19. PubMed ID: 24893041
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.
    López C; Silkenstedt E; Dreyling M; Beà S
    Blood Adv; 2024 Jul; 8(14):3652-3664. PubMed ID: 38748869
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
    Chiarle R; Budel LM; Skolnik J; Frizzera G; Chilosi M; Corato A; Pizzolo G; Magidson J; Montagnoli A; Pagano M; Maes B; De Wolf-Peeters C; Inghirami G
    Blood; 2000 Jan; 95(2):619-26. PubMed ID: 10627471
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
    Navarro Matilla B; García-Marco JA
    Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.
    Condoluci A; Rossi D; Zucca E; Cavalli F
    Curr Oncol Rep; 2018 Aug; 20(10):79. PubMed ID: 30132080
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Acalabrutinib for mantle cell lymphoma.
    Witzig TE; Inwards D
    Blood; 2019 Jun; 133(24):2570-2574. PubMed ID: 30967367
    [TBL] [Abstract][Full Text] [Related]  

  • 89. New strategies in the treatment of mantle cell lymphoma.
    Deng C; Lee S; O'Connor OA
    Clin Cancer Res; 2012 Jul; 18(13):3499-508. PubMed ID: 22700864
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.
    Williams ME; Bernstein SH; Jares P; Kahl BS; Witzig TE; Gordon LI
    Leuk Lymphoma; 2013 Sep; 54(9):1882-90. PubMed ID: 23363271
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Mantle cell lymphoma: advances in biology and therapy.
    Smith MR
    Curr Opin Hematol; 2008 Jul; 15(4):415-21. PubMed ID: 18536582
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma.
    Mussetti A; Kumar A; Dahi PB; Perales MA; Sauter CS
    Blood Rev; 2015 May; 29(3):143-52. PubMed ID: 25468719
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Emerging therapy for the treatment of mantle cell lymphoma.
    Rajguru S; Kahl BS
    J Natl Compr Canc Netw; 2014 Sep; 12(9):1311-8; quiz 1318. PubMed ID: 25190697
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Mantle Cell Lymphoma.
    Cheah CY; Seymour JF; Wang ML
    J Clin Oncol; 2016 Apr; 34(11):1256-69. PubMed ID: 26755518
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
    Gribbin C; Chen J; Martin P; Ruan J
    Leuk Lymphoma; 2024 Jan; 65(1):1-13. PubMed ID: 37800170
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Integrating monoclonal antibodies into the management of mantle cell lymphoma.
    Berinstein NL; Mangel J
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Evolving treatment strategies in mantle cell lymphoma.
    Edwin NC; Kahl B
    Best Pract Res Clin Haematol; 2018 Sep; 31(3):270-278. PubMed ID: 30213396
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies.
    Cohen JB; Zain JM; Kahl BS
    Am Soc Clin Oncol Educ Book; 2017; 37():512-525. PubMed ID: 28561694
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Mantle cell lymphoma: biological insights and treatment advances.
    Leonard JP; Williams ME; Goy A; Grant S; Pfreundschuh M; Rosen ST; Sweetenham JW
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):267-77. PubMed ID: 19717376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.